Citation Impact
Citing Papers
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
2011 Standout
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases
2008
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
Increased Thrombopoiesis and Platelet Activation in Hantavirus-Infected Patients
2015 StandoutNobel
Short-Term Effects of Nose-Only Cigarette Smoke Exposure on Glutathione Redox Homeostasis, Cytochrome P450 1A1/2 and Respiratory Enzyme Activities in Mice Tissues
2013 Standout
Chronic Myeloproliferative Disorders
2003
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
2015
Prothrombotic Effects of Environmental Stress
1995
Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature
2008
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
2012 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Adverse Drug Reactions to Systemic Antifungals Prevention and Management
1992
The Emerging Role of Recombinant-Activated Factor VII in Neurocritical Care
2004
Reduced transforming growth factor‐β1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura
2002
Phaeochromocytoma
2005 Standout
New Antithrombotic Drugs
2012
Essential thrombocythemia
2003
Haematological changes during acute mental stress
1989
Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial
2003
Stimulus‐specific defect in platelet aggregation in polycythemia vera
1994
Clinical significance of neutrophil CD177 mRNA expression in Ph‐negative chronic myeloproliferative disorders
2004
Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients
2005
Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected*
2002
Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura
2000
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
2015
Vascular disorders of the liver # †
2008 Standout
Surgical Management of Pheochromocytoma with the Use of Metyrosine
1990
The Evidence for the Use of Recombinant Human Activated Factor VII in the Treatment of Bleeding Patients With Quantitative and Qualitative Platelet Disorders
2007
Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
2005 Standout
Should a platelet limit of 600 × 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages
1998
Nanoparticles for drug delivery: The need for precision in reporting particle size parameters
2007
Platelet Activation and Atherothrombosis
2007 Standout
Antiplatelet Drugs
2012
Antiplatelet Drugs
2008
Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders
2004
Immune Thrombocytopenic Purpura
2002 Standout
Diabetes and Atherosclerosis
2002 Standout
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
2005 Standout
Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer
2002 Standout
Screening for Platelet Antibodies in Adult Idiopathic Thrombocytopenic Purpura: A Comparative Study Using Solid Phase Red Cell Adherence Assay and Flow Cytometry
2006
Sickle-cell disease
2010 Standout
Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer
2008
Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy
2008
Mechanisms of Response to Treatment in Autoimmune Thrombocytopenic Purpura
1989
Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age‐related changes and disease‐induced shifts
2004
Impaired Platelet Binding of Fibrinogen Due to a Lower Number of GPIIB/IIIA Receptors in Polycythemia Vera
1998 StandoutNobel
Advances in the diagnosis of idiopathic thrombocytopenic purpura
2000
Polycythemia vera and other primary polycythemias
2005
Low-Dose Aspirin for the Prevention of Atherothrombosis
2005
PRV-1 mRNA expression discriminates two types of essential thrombocythemia
2004
A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis
1995 Standout
Psychological Stress and the Human Immune System: A Meta-Analytic Study of 30 Years of Inquiry.
2004 Standout
Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients
2003
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
The chronic myeloproliferative disorders: Clonality and clinical heterogeneity
2004
Amphotericin B: 30 Years of Clinical Experience
1990
Platelet autoantibodies in patients with chronic liver disease
1995
Thrombotic complications in essential thrombocythemia with relatively low platelet counts
1997
Topographic diversity of fungal and bacterial communities in human skin
2013 StandoutNature
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
2005 StandoutNature
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
2005 Standout
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
2002 Standout
Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis
2005
Elevation of serum thrombopoietin precedes thrombocytosis in acute infections
2002
Wine, alcohol, platelets, and the French paradox for coronary heart disease
1992 Standout
Sidestream cigarette smoke accelerates atherogenesis in apolipoprotein E−/− mice
2001
Platelet aggregability in vivo is attenuated byverapamil but not bymetoprolol in patients with stable angina pectoris
1995
Specificity of autoantibodies in autoimmune thrombocytopenia
1982
Changes in distribution of platelet membrane glycoproteins in patients with myeloproliferative disorders
1977
Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia
2000
Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia
2000
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Inhibition of Endothelial Regeneration by Type-Beta Transforming Growth Factor from Platelets
1986 StandoutScience
Interactions of Agonists with Platelet α2-Adrenergic Receptors
1982 StandoutNobel
Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders
1989
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Recombinant Factor VIIa for Bleeding in Refractory Thrombocytopenia
2000
Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus
2016
Value of bone marrow biopsy in the diagnosis of essential thrombocythemia.
2004
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
2008 Standout
Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin
2003
Recombinant human natural autoantibodies against GPIIb/IIIa inhibit binding of autoantibodies from patients with AITP
1998
The pathogenesis of immune thrombocytopaenic purpura
2006
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Diagnosis of essential thrombocythemia at platelet counts between 400 and 600x10(9)/L. Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC).
2000
Thrombocytosis in patients with tumors producing colony-stimulating factor
1992 StandoutNobel
Impact of Psychological Factors on the Pathogenesis of Cardiovascular Disease and Implications for Therapy
1999 Standout
CD4+regulatory cells as a potential immunotherapy
2005 StandoutNobel
Activation of blood coagulation in cancer: Trousseau's syndrome revisited
1983
The structural and functional properties of thrombospondin
1986
Platelet Dysfunction in Type 2 Diabetes
2001
Platelet survival in childhood idiopathic thrombocytopenic purpura in remission
1976
Masked polycythemia Vera (mPV): Results of an international study
2013
Platelets in Myeloproliferative Disorders
1981
Polycythemia vera: myths, mechanisms, and management
2002
Thrombocytosis: platelet kinetics in neoplasia.
1974
Adventures in vascular biology: a tale of two mediators
2006
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum
2011 StandoutScience
Myeloproliferative disorders
2008
Plasma fibrinogen and ischemic heart disease risk factors.
1991
Is the Thrombopoietin Assay Useful for Differential Diagnosis of Thrombocytopenia? Analysis of a Cohort of 160 Patients with Thrombocytopenia and Defined Platelet Life Span
2001
Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study.
1991
Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura
1994
A randomized controlled trial of hemodilution therapy in acute ischemic stroke.
1984
Coronary Plaque Disruption
1995 Standout
Direct Binding Studies of Adrenergic Receptors: Biochemical, Physiologic, and Clinical Implications
1979 StandoutNobel
The Myeloproliferative Disorders
2006
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
2008
Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders
1990
Chronic Myeloproliferative Disorders: Improved Platelet Aggregation following Venesection
1978
Interobserver agreement for the assessment of handicap in stroke patients.
1988 Standout
Platelet Function in Essential Thrombocythemia
1978
Thrombocytosis: Diagnostic Evaluation, Thrombotic Risk Stratification, and Risk-Based Management Strategies
2011
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Thalidomide Use and Digital Gangrene
2006
Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study.
1991
Thrombospondin stimulates motility of human neutrophils.
1990 StandoutNobel
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Autoimmune thrombocytopenic purpura
1980
Therapy for myeloproliferative neoplasms: when, which agent, and how?
2014
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes
2007
Metal–Organic Framework (MOF)‐Based Drug/Cargo Delivery and Cancer Therapy
2017 Standout
Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor
1999 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD
1981 Standout
Thrombocytosis in patients with tumors producing colony-stimulating factor
1992 StandoutNobel
Vessel injury, platelet adherence, and platelet survival.
1983
Resistant Hypertension: Diagnosis, Evaluation, and Treatment
2008 Standout
Works of Jack Kutti being referenced
Diagnostic and Differential Criteria of Essential Thrombocythemia and Reactive Thrombocytosis
1996
The spleen and pooling of blood cells
1988
Diagnosis and Treatment of Polycythemia Vera and Possible Future Study Designs of the PVSG
2000
Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis
2001
No increased frequency of trisomies 8 and 9 by fluorescence in situ hybridization in untreated patients with essential thrombocythemia
2001
Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced‐intensity conditioning regimens
2006
Plasma erythropoietin by high‐detectability immunoradiometric assay in untreated and treated patients with polycythaemia vera and essential thrombocythaemia
1998
Clinical Experience with Recombinant Factor VIla in Patients with Thrombocytopenia
1996
An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia
2005
The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera
2010
Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment
2000
The management of thrombocytosis
1990
Evidence for a light chain restriction of glycoprotein Ib/IX and Ilb/IIIa reactive antibodies in chronic idiopathic thrombocytopenic purpura (ITP)
1995
Increased risk for vascular complications in PRV‐1 positive patients with essential thrombocythaemia
2003
The presence of a significant association between elevated PRV‐1 mRNA expression and low plasma erythropoietin concentration in essential thrombocythaemia
2003
Trends in the incidence of chronic Philadelphia chromosome negative (Ph‐) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983–99
2004
Patients with idiopathic myelofibrosis show increased CD34+ cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia
2002
In vitro and in vivo behavior of 111In‐labelled platelets: An experimental study of healthy male volunteers
1987
Smoking, Platelet Reactivity and Fibrinogen
1990
Light chain-restricted autoantibodies in chronic idiopathic thrombocytopenic purpura, but no evidence for circulating clonal B-lymphocytes
1996
Detection of platelet antibodies in chronic idiopathic thrombocytopenic purpura (ITP). A comparative study using flow cytometry, a whole platelet ELISA, and an antigen capture ELISA
1996
The effect of an adrenaline infusion on the splenic blood flow and intrasplenic platelet kinetics
1987
Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera
2004
Negligible Clinical Effects of Thalidomide in Patients with Myelofibrosis with Myeloid Metaplasia
2002
Impact of endogenous thrombopoietin levels on the differential diagnosis of essential thrombocythaemia and reactive thrombocytosis
1998
Splenic blood flow and intrasplenic platelet kinetics in relation to spleen volume
1987
Platelet Survival in Active Polycythaemia Vera with Reference to the Haematocrit Level
1971
Presence of a Non‐Splenic Platelet Pool in Man
1980
Platelets in the Myeloproliferative Syndrome
1975
Altered platelet function and circulation induced by amphotericin B in leukemic patients after platelet transfusion
1981
Evaluation of Platelet Reactivity in Diabetes Mellitus
1986
Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
1996
The Peripheral Platelet Count and ADP‐Induced Platelet Aggregation in Response to Metoprolol and Propranolol as Studied in Young Healthy Male Volunteers
1983
Platelet Activation in Response to Phlebotomy
1982
Platelet reactivity, fibrinogen and smoking
1987
Platelet Survival and Platelet Production in Acute Myocardial Infarction
1979
Comparison of Methods for Polycythemia Rubra Vera-1 mRNA Quantification in Whole-Blood Leukocytes and Purified Granulocytes
2004
ADP‐induced Platelet Aggregation in Young Female Survivors of Acute Myocardial Infarction and Their Female Controls
1985
Stress and Platelet Activation
1983
Platelet activation in response to phlebotomy. An experimental study of healthy blood donors.
1982
The Blood Volume in Pheochromocytoma Patients before and during Treatment with Phenoxybenzamine
1985
Platelet Survival and Platelet Production in Idiopathic Thrombocytopenic Purpura (ITP)
1974
Splenic blood flow and intrasplenic platelet kinetics in relation to spleen volume
1987
Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera
2005
The relation of thrombokinetics to bone marrow megakaryocytes in idiopathic thrombocytopenic purpura (ITP)
1975
ADP‐induced Platelet Aggregation and Metoprolol Treatment of Myocardial Infarction Patients
1985
Rapid Platelet Consumption in a Case of Metastatic Osteogenic Sarcoma of the Breast
1978
Platelet Survival in Man
1971
The effect of an adrenaline infusion on the splenic blood flow and intrasplenic platelet kinetics
1987